Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.
Do you have an idea of how your health system will address the large number of adalimumab biosimilars that are going to enter the market in the coming year?
There's a lot coming to market. And I think we're excited about it. We want to be an early adopter of biosimilar use. I think we want to be thoughtful though. So, we'll keep engaging our providers that already have familiarity with biosimilars within the rheumatology and GI [gastrointestinal] space and get their feedback.
But at the same time, we can't stop every single one of the therapies. We want to make sure we're making the right ones available to our patients. We're going to work with our payer colleagues to figure out which ones should we consider adding the formulary but at the end of the day, each different type of product that we stock is a cash and cash equivalent. We want to be good stewards of our organization's money, choose the best therapy that will provide the best outcomes for our patients, have good payer coverage and meet our providers, but we will probably move quickly and really leverage that to reduce our cost of care.